In our current study, we identified a risk model based on three prognostic signatures (TP53, CFL1, and UBA1) from publicly available data and further constructed a three-gene based prognostic nomogram which contained other clinical parameters (TNM stage and age at diagnosis) to predict 3-year and 5-year OS of HBV carriers with HCC development, which may be more effective in guiding the clinical decision-making of personalized treatment. Here, TP53 is linked to hepatocellular carcinoma.